CDK4 and dedifferentiated liposarcoma: Both alterations can be targeted by specific inhibitors (MDM2 antagonists RG7388 and Nutlin 3A (RG7112); CDK4/6 inhibitors palbociclib, ribociclib, abemaciclib and TQB3616) in experimental and clinical trials either used individually or in combination, especially in the therapy of DDLPS [98,100,103,105,106,107,108,109,110,111,112].